ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.

The article looks at a study which show that tumorigenicity of mechanistic target of rapamycin (mTORC3) in a rhabdomyosarcoma mouse model in which transgenic ETV7 expression accelerates tumor onset and promotes tumor penetrance. Topics discussed include E26 transformation–specific transcription factor ETV7 interacts with mTOR in the cytoplasm, human cancers activate mTORC3 at considerable frequency and tumor cell lines that lose mTORC3 expression become rapamycin-sensitive.